

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 01D0939515	(X3) Date Survey Completed 12/14/2021
Name of Provider or Supplier Southeast Medical Group	Street Address, City, State 1612 Highway 78 East, Suite 100, Oxford, AL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a review of the CMS (Centers for Medicare and Medicaid Services) CASPER reports and the MLE (Medical Laboratory Evaluation) Proficiency Testing (PT) evaluations, the surveyor determined the laboratory failed two consecutive testing events for Total Bilirubin (Chemistry testing), Events #2 and #3, 2021. These failures result in an initial unsuccessful PT participation. The findings include: 1. A review of the CASPER reports (#153 and #155) revealed the laboratory scored 40 % (percent) for Total Bilirubin for Event #2, 2021 and 20 % for Event #3, 2021. 2. The surveyor reviewed the MLE PT evaluations and confirmed the above noted scores.</p>

D2096

ROUTINE CHEMISTRY

CFR(s): 493.841(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a review of the CMS (Centers for Medicare and Medicaid Services) CASPER reports and the MLE (Medical Laboratory Evaluation) Proficiency Testing (PT) evaluations, the surveyor determined the laboratory failed to satisfactorily perform for two consecutive testing events for Total Bilirubin (Chemistry testing), Events #2 and #3, 2021. These failures result in an initial unsuccessful PT participation. The findings include: 1. A review of the CASPER reports (#153 and #155) revealed the laboratory scored 40 % (percent) for Total Bilirubin for Event #2, 2021 and 20 % for Event #3, 2021. 2. The surveyor reviewed the MLE PT evaluations and confirmed the above noted scores.